Artivion (AORT) Q2 EPS Jumps 243%
Artivion (NYSE:AORT), a leader in cardiac and vascular surgical devices, reported its Q2 2025 results on August 7, 2025. The company posted non-GAAP earnings per share of $0.24, outperforming the analyst estimate of approximately -$0.00 (non-GAAP) and marking a sharp increase from $0.07 per share (non-GAAP) in Q2 2024. Revenue (GAAP) came in at $113.0 million, ahead of the $108.03 million non-GAAP consensus estimate and 15% above the prior-year figure (GAAP). Management described the period as a standout quarter, citing broader product demand and ongoing recovery from previous supply chain and cybersecurity disruptions. Following these results, the company raised its full-year 2025 revenue and adjusted EBITDA guidance, reflecting confidence in its business trajectory and pipeline development.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Artivion specializes in technologies for cardiac and vascular surgery. Its core offerings include mechanical heart valves, aortic stent grafts, surgical sealants, and preservation services for transplant tissues. Physicians use its products in complex surgeries, often for life-threatening heart and vascular conditions.
Source Fool.com
